Abilitypharma

Abilitypharma company information, Employees & Contact Information

Explore related pages

Related company profiles:

Ability Pharmaceuticals is a clinical-stage biopharmaceutical company committed to develop first-in-class therapies that address unmet medical needs in the oncology space. AbilityPharma's is currently conducting, with ABTL0812, the most advanced asset, an international multi-center, double-blind, placebo-controlled phase 2b clinical trial in patients with metastatic pancreatic cancer to investigate ABTL0812 as first-lin therapy in combination with FOLFIRINOX chemotherapy. The study includes reference centers in Spain, France, United States and Israel. ABTL0812 has finished with very positive results a phase 2a clinical trial as first-line therapy in endometrial cancer and in squamous NSCLC in combination with paclitaxel and carboplatin. The study included leading institutions in Spain and France (Vall d’Hebron Institut d’Oncologia – VHIO, Institut Gustave Roussy, Centre Léon Bérard). ABTL0812 is the first cancer drug killing tumor cells through potent cytotoxic autophagy via inhibition of the Akt/mTOR axis, and the induction of robust endoplasmic reticular stress (ER Stress). Its unique mechanism of action was partially published at Clinical Cancer Research in December 2015 and fully characterized at Autophagy journal in May 2020. The compound has also immunomodulatory effects, turning "cold" immunogenic tumors into "hot" immunogenic. The compound is active as standalone treatment, it has synergy with chemotherapy, and it has synergy with anti PD1 therapies. The product has potential in several cancer types as first-line and maintenance therapy including lung, endometrial, pancreatic, breast, head and neck cancer, glioblastoma, cholangiocarcinoma and the pediatric cancer neuroblastoma. ABTL0812 has been granted Orphan Drug Designation for pancreatic cancer, neuroblastoma, and biliary tract cancer, by the US FDA and the European EMA. Development and marketing rights for Greater China granted to SciClone Pharmaceuticals, Inc.

Company Details

Employees
23
Founded
-
Address
Avinguda Parc Tecnològic, 3, Cerdanyola Del Vallès,catalonia 08290,spain
Phone
+34 935 86 89 77
Email
co****@****rma.com
Industry
Biotechnology
Keywords
Barcelona.
HQ
Cerdanyola del Vallès, Catalonia
Looking for a particular Abilitypharma employee's phone or email?

Abilitypharma Questions

News

AbilityPharma’s IBRILATAZAR (ABTL0812) doubles overall survival in patients with squamous non-small cell lung cancer - BioSpace

AbilityPharma’s IBRILATAZAR (ABTL0812) doubles overall survival in patients with squamous non-small cell lung cancer BioSpace

AbilityPharma receives funds to advance pancreatic cancer trial - Clinical Trials Arena

AbilityPharma receives funds to advance pancreatic cancer trial Clinical Trials Arena

New pathway to attack tumor cells identified - uab.cat

New pathway to attack tumor cells identified uab.cat

Project led by lecturer José Miguel Lizcano awarded RETOS collaboration grant - uab.cat

Project led by lecturer José Miguel Lizcano awarded RETOS collaboration grant uab.cat

Top Abilitypharma Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant